CreativeOne Wealth LLC Purchases 305 Shares of Danaher Co. (NYSE:DHR)

CreativeOne Wealth LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 24.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,542 shares of the conglomerate’s stock after buying an additional 305 shares during the quarter. CreativeOne Wealth LLC’s holdings in Danaher were worth $429,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in DHR. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the second quarter worth about $25,000. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter worth approximately $25,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher during the third quarter valued at approximately $40,000. MFA Wealth Advisors LLC bought a new position in shares of Danaher during the second quarter valued at approximately $51,000. Finally, Financial Connections Group Inc. purchased a new stake in Danaher in the second quarter worth $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. Stifel Nicolaus raised their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, UBS Group reduced their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Price Performance

Shares of NYSE DHR opened at $239.69 on Monday. The firm has a market cap of $173.12 billion, a P/E ratio of 45.74, a PEG ratio of 4.41 and a beta of 0.85. Danaher Co. has a twelve month low of $215.68 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average of $254.59 and a 200 day moving average of $259.41.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. As a group, research analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.